期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 22, 期 34, 页码 7718-7726出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v22.i34.7718
关键词
Oral administration; Nanotherapeutic; Cellspecificity; Inflammatory bowel disease
资金
- National Natural Science Foundation of China [51503172, 81571807]
- Fundamental Research Funds for the Central Universities [SWU114086, XDJK2015C067]
- Scientific Research Foundation for the Returned Overseas Chinese Scholars (State Education Ministry)
- Department of Veterans Affairs
- National Institutes of Health of Diabetes and Digestive and Kidney [RO1-DK-071594]
- Career Scientist Award from the Department of Veterans Affairs
Inflammatory bowel disease (IBD) is a chronic relapsing disease in gastrointestinal tract. Conventional medications lack the efficacy to offer complete remission in IBD therapy, and usually associate with serious side effects. Recent studies indicated that nanoparticle-based nanotherapeutics may offer precise and safe alternative to conventional medications via enhanced targeting, sustained drug release, and decreased adverse effects. Here, we reviewed orally cell-specific nanotherapeutics developed in recent years. In addition, the various obstacles for oral drug delivery are also reviewed in this manuscript. Orally administrated cell-specific nanotherapeutics is expected to become a novel therapeutic approach for IBD treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据